Clinical trial
A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition to Rituximab in Adult Patients With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT05338190 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition to Rituximab in Adult Patients With Persistent or Chronic Immune Thrombocytopenia (ITP)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 14, 2022
- Completion date
- November 14, 2027
- Enrollment
- 132 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
primary immune thrombocytopenia (itp)